MedTrace Logo

Peyronie's Disease Treatment Protocol

NCT02072018 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2014-02-26

No results posted yet for this study

Summary

Treatment of Peyronie's disease remains difficult. The purpose of this study is to test the safety and efficacy of a new compound to treat this disease.

Conditions

  • Peyronie's Disease

Interventions

DRUG

H-100

H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.

DRUG

Placebo

Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.

Sponsors & Collaborators

  • Hybrid Medical

    lead INDUSTRY

Principal Investigators

  • Jeffry Twidwell, MD · North Memorial Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-06-30
Primary Completion
2013-12-31
Completion
2013-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02072018 on ClinicalTrials.gov